GlassScriptPhysician profile
Muhammad A Azam
NPI 1740244367
$28,003.78
in general payments reported to CMS, 2019-2025
34 companies · $751 in 2025
The $751 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $6,118 · 2021: $566 · 2022: $2,915 · 2023: $845 · 2024: $757 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,348.33 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $21,070.83 | 2019-2024 | Enhertu |
| Biohaven Pharmaceutical Holding Company LTD. | $1,979.86 | 2022 | |
| Abbvie INC. | $1,114.37 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Astrazeneca Pharmaceuticals LP | $801.03 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $737.13 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $309.60 | 2020-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.83 | 2020-2023 | Jardiance, Synjardy |
| Nestle Healthcare Nutrition INC. | $195.42 | 2021-2023 | |
| Novo Nordisk INC | $168.16 | 2022-2025 | Wegovy |
| Pfizer INC. | $155.65 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $140.42 | 2019-2022 | |
| Astellas Pharma US INC | $106.58 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $88.87 | 2019-2023 | |
| Allergan, INC. | $84.69 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.10 | 2022-2024 | Xifaxan, Trulance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $73.73 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bayer Healthcare Pharmaceuticals INC. | $71.00 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $70.14 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Sunovion Pharmaceuticals INC. | $59.92 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $59.80 | 2019-2023 | Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $48.91 | 2025 | Zoryve |
| Bausch Health US, LLC | $43.76 | 2022-2023 | Aplenzin |
| Amgen INC. | $38.10 | 2022-2025 | Otezla, Repatha |
| Amarin Pharma, INC. | $31.85 | 2019 | |
| Impulse Dynamics (USA) INC. | $26.97 | 2022 | |
| Dexcom, INC. | $25.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.42 | 2022 | |
| Mannkind Corporation | $23.26 | 2020 | |
| Vanda Pharmaceuticals INC. | $20.59 | 2019 | |
| Corcept Therapeutics | $20.55 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $19.02 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.61 | 2019 | |
| Metacel Pharmaceuticals LLC | $17.73 | 2022 | |
| Eisai INC. | $17.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Azam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.